Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. ABAB secretion in S. cerevisiae.
  • Fig. S2. Transformation competency of S. cerevisiae and S. boulardii.
  • Fig. S3. Diagram of optimization procedure for S. boulardii transformation.
  • Fig. S4. Transformation of yeasts under different conditions.
  • Fig. S5. Diagram of targeted deletion of URA3 loci by homologous recombination in chromosome V of S. boulardii.
  • Fig. S6. Phenotypic characteristics of S. boulardii URA3Δ::aphA1/Δ::ble.
  • Fig. S7. PCR validation of S. boulardii URA3Δ::aphA1/Δ::ble.
  • Fig. S8. PCR validation of pPL5071 spin-off and curing of 2-μm plasmid from S. boulardii URA3−/−.
  • Fig. S9. Diagram of S. boulardii tolerance assessment in antibiotic-treated mice.
  • Fig. S10. Relative weight change after oral administration of S. boulardii to antibiotic-treated mice.
  • Fig. S11. Diagram of oral administration of Sb-ABAB for CDI prevention in mice.
  • Fig. S12. Cecal histology and inflammation in mice in the CDI prevention study.
  • Fig. S13. Efficacy of oral Sb-ABAB against CDI in hamsters.
  • Fig. S14. Diagram of oral administration of Sb-ABAB for treating primary CDI.
  • Fig. S15. Intestinal histopathology, inflammation, and fecal bacterial counting after treatment with Sb-ABAB against primary CDI.
  • Fig. S16. Diagram of oral administration of Sb-ABAB for preventing recurrent CDI.
  • Table S1. Tetra-specific ABAB is a broadly neutralizing antibody.
  • Table S2. A summary of ABAB-neutralizing activity against toxins produced by C. difficile clinical isolates from the Emerging Infections Program Clostridium difficile Surveillance Project.
  • Legend for data file S1
  • References (8897)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: